| Pair Name | Oridonin, Cisplatin | ||
| Phytochemical Name | Oridonin (PubChem CID: 5321010 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Oridonin, Cisplatin | |||
| Disease Info | [ICD-11: 2B70] | Esophageal cancer | Investigative | |
| Biological Phenomena | Induction-->DNA damage | |||
| Gene Regulation | Down-regulation | Expression | GSH | KEGG ID N.A. |
| Up-regulation | Expression | H2AX | hsa3014 | |
| Down-regulation | Expression | RAD51 | hsa5888 | |
| Up-regulation | Expression | ROS1 | hsa6098 | |
| In Vitro Model | KYSE-30 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_1351 |
| Result | These results suggest that ORI can synergistically enhance the effect of CIS, and GSH deficiency and p53 mutation, might be biomarkers for the combinational usage of ORI and CIS. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells. Anticancer Drugs. 2022 Jan 1;33(1):e444-e452. doi: 10.1097/CAD.0000000000001237. | Click |
